Accepted for Publication: May 29, 2020.
Published Online: June 17, 2020. doi:10.1001/jamainternmed.2020.3030
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Thompson AE et al. JAMA Internal Medicine.
Corresponding Author: Sanja Jelic, MD, Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Vagelos College of Physicians and Surgeons, 630 W 168th St, PH8 Center, Room 101, New York, NY 10032 (email@example.com).
Author Contributions: Dr Jelic had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Thompson and Ranard served as co–first authors and contributed equally to the work.
Study concept and design: Thompson, Ranard, Jelic.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Wei.
Obtained funding: Jelic.
Administrative, technical, or material support: Thompson, Ranard, Jelic.
Study supervision: Thompson, Ranard, Jelic.
Conflict of Interest Disclosures: None reported.
Funding/Support: This work was supported by National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NHLBI) grants R01HL106041 and R01HL137234 (Dr Jelic).
Role of the Funder/Sponsor: The NIH/NHLBI had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Information: The study was registered on ClinicalTrials.gov on May 25, 2020, owing to the emergency nature of the treatment being administered based on clinical decision to critically ill patients with severe COVID-19 hypoxemic respiratory failure.